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Abstract
Background: Cancer affects older adults disproportionately. The disease is often difficult to diagnose and treat due
to co-morbidities and performance status, and patients tend to discontinue chemotherapy prematurely. There are
no systemic studies of the reasons and factors that create a higher withdrawal rate in older acute leukemia
patients. This study tried to understand the initial characteristics, blood counts and bone marrow measurements in
older acute leukemia patients by comparing them with a younger group to provide information and assistance in
early clinical diagnosis, treatment and reasons for treatment withdrawal.
Methods: Using retrospective medical record reviews, we examined clinical characteristics and chemotherapy
completion status in the patients of two groups (age ≥ 60, n = 183 and age <60, n = 183) who were diagnosed
with acute leukemia for the first time and were hospitalized in Union Hospital Affiliated with Fujian Medical
University from 2004 to 2008.
Results: There were no statistical differences in initial presenting symptoms of fatigue (67.2% vs. 57.9%, P>0.05)
and pallor (53% vs. 59.6%, P>0.05) between the two groups, but older patients demonstrated more underlying
diseases including lung infections (25.7%, P = <0.001), cardiovascular disease (4.4%, P = 0.007), and hypertension
(20.8%, P =< 0.001). The complete remission rate after chemotherapy (1 to 2 courses) was 49.5% in the older group
and 66.7% in the younger group (c
2 = 6.202, P = 0.013). The percentage of patients age 60 and older who
prematurely discontinued chemotherapy (50.3%), mainly due to the influences of traditional Chinese concept of
critical illness, financial difficulties, and intolerance to adverse reactions to chemotherapy, was significantly higher
than that of younger patients (37.7%) (c
2 = 5.866, P = 0.015).
Conclusions: A comprehensive approach to diagnosis, treatment selection, and toxicity management, and
implementing strategies to enhance treatment compliance may improve outcomes in older adults with acute leukemia.
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Background
Over the next 20 to 40 years, cancer cases and deaths will
double worldwide as populations’ age and longevity
increases [1]. Cancer disproportionately affects the
elderly and as life expectancies increase worldwide, the
incidence of malignancy rises [2]. In the United States,
death from major tumors by age range from 71-77 years
increase dramatically, and the expectation is that other
countries will see similar numbers [3]. When cancer
occurs in older adults, they tend to have more co-mor-
bidities. Coronary heart disease (CHD), chronic obstruc-
tive pulmonary disease (COPD), hypertension, diabetes,
non-specific pain, dementia and other diseases of older
adults are more common as people age. These co-
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cer, leading to potential delays in diagnosis.
The onset of acute leukemia (AL) is often difficult to
detect as the disease progresses relatively slowly with
few invasive signs and rare early manifestations. Patients
often seek medical care because of perceived complica-
tions from existing diseases. The diagnosis of disease
relies on symptom assessment, laboratory and radiology
tests, leading to the potential for missed diagnosis dur-
ing the early stages of disease in some leukemias. With-
o u tp r o m p td i a g n o s i sa n dt r eatment, particularly in
acute myelogenous leukemia, elderly patients will die of
their disease within a short time period of weeks or
months [4].
A c u t el e u k e m i ai n c l u d e sa c u te lymphocytic leukemia
and acute myelogenous leukemia. The remission rate of
acute leukemia in elderly patients is low, mortality is high,
and survival time is short [5-8]. Induction therapy for
acute leukemia is strenuous, and therapy determinations
are often made based on age, performance status, and co-
morbidities combined with other factors such as cytoge-
netics [9]. Many older adults are not offered or are not eli-
gible for clinical trials, and most studies are focused on a
younger population of patients, rather than elderly patients
who are frail. Treatment options for leukemia are more
limited in older patients because of co-morbidities [10].
Some studies report an association between age and ther-
apy toxicity in the elderly, but the relationship between
age-related side effects and targeted therapies is not clear;
and data on the relationship of pharmacokinetics and
pharmacodynamics and the impact of age are limited [11].
Even when eligible for treatment, elderly patients may
choose palliative care options or prematurely discontinue
therapy [10]. Several studies have shown that adherence to
therapy was impacted by mood variables and attitude
toward cancer [12-14]. Newer targeted therapies may pro-
vide new treatment options for older individuals, but addi-
tional studies are needed [15].
There is a greater need to understand the implications
influencing treatment of AL in the elderly. This study eval-
uates a series of cases of AL in elderly patients (age ≥ 60)
and compares clinical features and characteristics with a
younger comparison group (age < 60) in Fujian Province,
P.R. China, to determine the rate and causes for patients
discontinuing chemotherapy prematurely.
Methods
The study uses a retrospective comparison design to ana-
lyze five years of data captured from archived medical
records for patients with acute leukemia in a hospital in
Fujian. The study was reviewed and approved by the
Ethics Committee of Fujian Medical University. No
informed consent was required per the Ethics Committee
decision as only patient data were used, patient anonymity
was insured by the researchers, and there was no risk to
patients.
Patients
Hospitalized patients treated in the Department of
Hematology in Union Hospital Affiliated with Fujian
Medical University in Fujian Province from January
2004 to December 2008 with archived medical records
in the medical record room were included in the study.
Retrospectively reviewed medical record data were used
to divide patients into two groups: the elderly group of
183 patients with age ≥ 60 who met inclusion criteria,
and the younger group of 183 patients with an age < 60
who met inclusion criteria. Inclusion criteria in the
elderly group were previously untreated patients with a
cytological examination of bone marrow before treat-
ment began and with results consistent with the diag-
nostic criteria of acute leukemia (ALL and AML). The
diagnostic criteria for acute leukemia were based pri-
marily on clinical characteristics, blood and bone mar-
row examination by clinical physicians. The confirmed
diagnosis was based on bone marrow examination.
French-American-British (FAB) classification was used
in this study. ALL was classified into L1, L2 and L3
while AML was classified into M0 to M7 subtypes. Case
distribution for the elderly group were 28 cases in 2004,
38 cases in 2005, 34 cases in 2006, 47 cases in 2007,
and 36 cases in 2008. A total of 183 patients under the
age of 60 with acute leukemia were randomly selected
as a comparison group using a random number table
with an equal number of younger patients as that of
elderly patients in each year. No children were included.
Methods
Archived medical records were reviewed by the research-
ers and data was recorded to include gender and age,
course of disease, initial symptoms, complete blood
count with white blood cell differential results at first
visit, diagnosis and classification, underlying diseases and
complications, chemotherapy situation, chemotherapy
regimen (’see Additional file 1: table S1’), treatment
course of chemotherapy, whether chemotherapy was
stopped during treatment and when, and cause of discon-
tinuing chemotherapy, remission status as defined by
Cheson BD, et al. in 2003, [16] and payment method for
medical expenses.
Statistical analysis
Numbers and percentages of categorical variables were
analyzed using the chi-square test. When the number
of variables in a cell was less than five, Fisher’s exact
test was used. Multiple logistic regression analysis was
used to determine whether the difference between the
two groups was still statistically significant after
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tics. Age in the two groups was shown as mean ± stan-
dard deviation (SD), and tested using an independent
t-test. Statistical significance was considered as two-
sided p < 0.05. All data and comparisons were ana-
lyzed using SPSS statistical software (version 15.0,
SPSS Inc., Chicago, IL).
Results
Characteristics at Presentation
A total of 366 medical records were retrospectively
reviewed with equal numbers of patient records in the
group of patients ≥ 60 years of age (n = 183) and <60
years of age (n = 183). In the younger group, there
were 111 males and 72 females with an average age of
34.4 ± 1.0 years old and a range of 15 to 59 years old.
In the older group, there were 116 males and 67
females. In the older group, 140 were between 60 to 74
years and 43 were more than 75 years with an average
age of 70.1 ± 0.5. The definition of elderly developed by
the Asia-Pacific Institute of Studies in October 1980
was used to classify the elderly group as age 60 years or
above. Baseline characteristics, co-morbidities, and sta-
tistical significance of findings of the elderly group are
summarized and compared to the younger group in
Table 1. As expected, more patients in the elderly
group presented with co-morbidities of lung infection,
cardiovascular disease, hypertension and COPD. The
younger group presented with a greater incidence of
Hepatitis B.
Classification of Disease and Symptoms
Comparisons of initial manifestations between the
elderly patient group and the younger patient group are
shown in Table 2 and include the types of acute leuke-
mia in French-American-British classification, initial
symptoms, hematology, and degree of cellularity of bone
marrow. Compared with younger patients, more elderly
patients had acute myeloid leukemia [AML, 89.6% (164/
183) vs. 63.4% (116/183)]. Fewer elderly patients had
extremely active bone marrow cellularity (33.3% vs.
49.2%). The initial manifestations of disease in elderly
patients were fatigue (67.2%) and pallor (53.0%) as com-
pared to pallor (59.6%) and fatigue (57.9%) in the
younger group.
Remission Status and Complications
Table 3 shows discontinuation of chemotherapy, remis-
sion status and complications caused by chemotherapy.
In the elderly group, 92 patients (50.3%) withdrew from
chemotherapy (45 patients did not receive chemotherapy
after diagnosis; 39 patients withdrew after the first che-
motherapy cycle; 8 patients withdrew after the second
chemotherapy cycle). In the younger group, a total of 69
patients (37.3%) withdrew from chemotherapy (29
patients did not receive chemotherapy after diagnosis;
32 patients withdrew after the first chemotherapy cycle;
8 patients withdrew after the second chemotherapy
cycle). There was significant difference between the two
groups in discontinuing chemotherapy (P =0 . 0 1 5 ) .
Younger patients completing therapy had a significantly
Table 1 Patient Characteristics
Total Type of Leukemia-ALL
2 Type of Leukemia-AML
2
Younger
Group
(n = 183)
Elderly
Group
(n = 183)
p-value
1 Younger
Group
(n = 67)
Elderly
Group
(n = 19)
p-value
1 Younger
Group
(n = 116)
Elderly
Group
(n = 164)
p-value
1
Age (years) 34.4 ± 13.1 70.1 ± 6.4 <0.001* 30.2 ± 13.3 69.3 ± 5.5 <0.001* 36.8 ± 12.4 70.2 ± 6.5 <0.001*
Male gender 111 (60.7) 116 (63.4) 0.59 46 (68.7) 10 (52.6) 0.196 65 (56.0) 106 (64.6) 0.146
Married 131 (71.6) 183 (100.0) <0.001* 34(50.7) 19 (100) <0.001* 97 (83.6) 164 (100) <0.001*
Smoking 14 (7.7) 34 (18.6) 0.002* 3 (4.5) 3 (15.8) 0.122 11 (9.6) 31 (18.9) 0.032*
Alcohol use** 4 (2.2) 12 (6.6) 0.041* 1 (1.5) 0 (0) 1.000 3 (2.6) 12 (7.3) 1.000
History of carcinoma*** 4 (2.2) 4 (2.2) 1.000 0 (0) 1 (5.3) 0.221 4 (3.4) 3 (1.8) 0.454
Lung infection 18 (9.8) 47 (25.7) <0.001* 3 (4.5) 3 (15.8) 0.119 15 (12.9) 44 (26.8) 0.005*
Cardiovascular disease 0 (0.0) 8 (4.4) 0.007* 0 (0) 0 (0) - 0 (0) 8 (4.9) 0.023*
Hypertension 3 (1.6) 38 (20.8) <0.001* 2 (3.0) 5 (26.3) 0.005* 1 (0.9) 33 (20.1) <0.001*
Diabetes 4 (2.2) 14 (7.7) 0.016* 0 (0) 2 (10.5) 0.047* 4 (3.4) 12 (7.3) 0.200
COPD 0 (0.0) 9 (4.9) 0.004* 0 (0) 0 (0) - 0 (0) 9 (5.5) 0.012*
Hepatitis B 14 (7.7) 8 (4.4) 0.187 9 (13.4) 3 (15.8) 0.723 5 (4.3) 5 (3.0) 0.575
Data were represented as n (%) except age was as mean ± SD
SD = standard deviation; COPD = chronic obstructive pulmonary disease
1 Chi-square test or Fishers’ exact test was used for categorical data and independent t-test was used for age.
2 The types were based on French-American-British classification.
*Indicates significant differences between two groups, p < 0.05.
**Consuming 5 or more drinks per day.
***History of other malignant tumors occurring before the diagnosis of acute leukemia.
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patients (49.5%). Interesting l y ,t h ed i f f e r e n c ei nr e m i s -
sion status was only significant in patients with AML if
the acute leukemia classification was considered (Table
4). Remission status stratified by type of leukemia and
completion or non-completion of therapy is shown in
Table 4. As for complications from chemotherapy, a
higher percentage of elderly patients suffered from car-
diotoxicity (7.1% vs. 0.5%) and lung infection (49.2% vs.
29.0%) when compared to younger patients. Multiple
logistic regression analysis was used to adjust for smok-
ing, drinking, lung infection, hypertension, diabetes and
other factors.
Causes of Discontinuing Chemotherapy
Approximately one half of elderly patients stopped che-
motherapy before completing therapy (50.3%) while
there were 37.7% younger patients discontinued che-
motherapy. The main reasons that led to discontinuing
chemotherapy in elderly group were increasing severity
of leukemia symptoms (42.4%), economic difficulty
(37.0%), and the patient’s inability to tolerate adverse
effects (12.0%) (Table 5). The main reason for younger
patients to discontinue chemotherapy was economic dif-
ficulty (66.7%), next reason was increasing severity of
leukemia symptoms (21.7%).
Discussion
A c u t el e u k e m i ai ne l d e r l yp a t i ents is a severe, high-risk
hematological disease whose incidence is increasing with
the age of the population [17]. Survey data in the United
States in 2006 (Surveillance, Epidemiology and End
Results, SEER) showed that the incidence rate of acute
myeloid leukemia (AML) was 16.9/10 million in the
population 65 years and over [18]. Survival rates have
not improved for older patients with acute leukemia, in
p a r tb e c a u s et h e ym a yn o tb eo f f e r e da g g r e s s i v et h e r a -
pies and clinical trials, or they may choose to forego
chemotherapy or choose to stop therapy before comple-
tion [6,9]. This study shows that older patients (≥ 60)
present with more co-morbidities than younger patients,
have a poorer remission status and more complications
Table 2 Type of Acute Leukemia, Initial Symptoms, Hematology and Degree of Bone Marrow Cellularity
Total Type of Acute Leukemia-ALL Type of Acute Leukemia-AML
Initial symptom Younger
Group
(n = 183)
Elderly
Group
(n = 183)
p-value
1 Younger
Group
(n = 67)
Elderly
Group
(n = 19)
p-value
1 Younger
Group
(n = 116)
Elderly
Group
(n = 164)
p-value
1
Hypodynamia 106 (57.9) 123 (67.2) 0.066 39 (58.2) 11 (57.9) 0.980 67 (57.8) 112 (68.3) 0.071
Pale face 109 (59.6) 97 (53.0) 0.206 39 (58.2) 6 (31.6) 0.040* 70 (60.3) 91 (55.5) 0.418
Fever 78 (42.6) 61 (33.3) 0.067 31 (46.3) 6 (31.6) 0.254 47 (40.5) 55 (33.5) 0.232
Hemorrhagic dermatologic mucosa 25 (13.7) 25 (13.7) 1.000 7 (10.4) 2 (10.5) 1.000 18 (15.5) 23 (14.0) 0.728
Dizziness 29 (15.8) 20 (10.9) 0.167 12 (17.9) 3 (15.8) 1.000 17 (14.7) 17 (10.4) 0.279
WBC infiltration** 17 (9.3) 24 (13.1) 0.246 9 (13.4) 4 (21.1) 0.471 8 (6.9) 20 (12.2) 0.145
Lower extremity edema 0(0) 5(2.73) 0.024 0 (0) 2 (10.5) 0.047* 0 (0) 3 (1.8) 0.269
Myalgias 5(2.73) 5(2.73) 1.000 0 (0) 0 (0) - 5 (4.3) 5 (3.0) 0.575
White cell count (10
9/L) 0.139 0.057 0.012*
<4 56 (30.6) 69 (37.7) 28 (41.8) 3 (15.8) 28 (24.1) 66 (40.2)
4 - 10 29 (15.8) 18 (9.8) 10 (14.9) 2 (10.5) 19 (16.4) 16 (9.8)
>10 98 (53.6) 96 (52.5) 29 (43.3) 14 (73.7) 69 (59.5) 82 (50.0)
Hemoglobin (g/L)
2 0.549 0.078 0.336
Abnormal 168 (91.8) 171 (93.4) 60 (89.6) 14 (73.7) 108 (93.1) 157 (95.7)
Normal 15 (8.2) 12 (6.6) 7 (10.4) 5 (26.3) 8 (6.9) 7 (4.3)
Platelets (10
9/L) 0.018* 0.273 0.127
≦ 10 59 (32.2) 39 (21.3) 25 (37.3) 4 (21.1) 34 (29.3) 35 (21.3)
>10 124 (67.8) 144 (78.7) 42 (62.7) 15 (78.9) 82 (70.7) 129 (78.7)
Bone marrow cellularity 0.014* 0.400 0.002*
Severely hypercellular 90 (49.2) 61 (33.3) 28 (41.8) 11 (57.9) 62 (53.4) 50 (30.5)
Moderately hypercellular 38 (20.8) 58 (31.7) 13 (19.4) 1 (5.3) 25 (21.6) 57 (34.8)
Normocellular 31 (13.1) 39 (21.3) 15 (22.4) 5 (26.3) 16 (13.8) 34 (20.7)
Hypocellular 24 (13.1) 25 (13.7) 11 (16.4) 2 (10.5) 13 (11.2) 23 (14.0)
1 Chi-square test was used for categorical data.
2 Abnormal was defined as hemoglobin 110 g/L for female and hemoglobin 120 g/L for male.
*Indicates significant differences between two groups, p < 0.05.
**White blood cell infiltration
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Total Type of Leukemia-ALL Type of Leukemia-AML
Variables Younger
Group
(n = 183)
Elderly
Group
(n = 183)
p-value
1 Adjusted
P
3
Younger
Group
(n = 67)
Elderly
Group
(n = 19)
p-value
1 Adjusted P
4 Younger
Group
(n = 116)
Elderly
Group
(n = 164)
p-value
1 Adjusted P
4
Chemotherapy dropout 69 (37.7) 92 (50.3) 0.015* - 20 (29.9) 9 (47.4) 0.154 - 49 (42.2) 83 (50.6) 0.167 -
Remission status
2 0.013* 0.008* 0.415 0.422 0.018 0.010*
Partial 38 (33.3) 46 (50.5) 17 (36.2) 5 (50.0) 21 (31.3) 41 (50.6)
Complete 76 (66.7) 45 (49.5) 30 (63.8) 5 (50.0) 46 (68.7) 40 (49.4)
Complication caused by chemotherapy
Mouth ulcer 31 (16.9) 23 (12.6) 0.238 0.728 13 (19.4) 3 (15.8) 1.000 0.899 18 (15.5) 20 (12.2) 0.424 0.642
Gastrointestinal disorder 34 (18.6) 37 (20.2) 0.692 0.170 18 (26.9) 5 (26.3) 0.962 0.629 16 (13.8) 32 (19.5) 0.211 0.127
Cardiotoxicity 1 (0.5) 13 (7.1) 0.001* 0.047* 0 (0) 1 (5.3) 0.221 - 1 (0.9) 12 (7.3) 0.017 0.068
Liver damage 26 (14.2) 29 (15.8) 0.661 0.607 9 (13.4) 5 (26.3) 0.179 0.228 17 (14.7) 24 (14.6) 0.996 0.987
Lung infection 53 (29.0) 90 (49.2) <0.001* 0.024* 13 (19.4) 9 (47.4) 0.014 0.025 40 (34.5) 81 (49.4) 0.013 0.138
Angina 89 (48.6) 74 (40.4) 0.115 0.698 33 (49.3) 8 (42.1) 0.582 0.827 56 (48.3) 66 (40.2) 0.182 0.669
Intestinal infection 38 (20.8) 36 (19.7) 0.795 0.951 17 (25.4) 4 (21.1) 1.000 0.538 21 (18.1) 32 (19.5) 0.767 0.871
Fungal infection 36 (19.7) 51 (27.9) 0.065 0.285 10 (14.9) 6 (31.6) 0.100 0.051 26 (22.4) 45 (27.4) 0.341 0.755
Skin hemorrhage 48 (26.2) 29 (15.8) 0.013* 0.019* 14 (20.9) 4 (21.1) 1.000 0.689 34 (29.3) 25 (15.2) 0.004 0.015*
1 Chi-square test was used.
2 The remission status was for those patients who finished the whole chemotherapy.
3 Multiple logistic regression analysis that adjusted for smoking, alcohol use, lung infection, hypertension, diabetes, type of leukemia, platelet and bone marrow cellularity
4 Multiple logistic regression analysis that adjusted for smoking, alcohol use, lung infection, hypertension, diabetes, platelet and bone marrow cellularity
* Indicates significant difference between two groups, p < 0.05.
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motherapy before completing prescribed cycles due to
severity of disease and economic factors. As the age of
acute leukemia patients increases, adherence to che-
motherapy regiment decreases [13]. Our findings sug-
gest that a careful history and physical examination at
presentation, treatment selection based on multiple fac-
tors rather than age, aggressive management of compli-
cations of therapy and co-morbidities, and sufficient
support resources to remain in therapy are needed to
improve outcomes in older leukemia patients.
The performance status of a patient may determine the
type of induction therapy offered. If a patient is perceived
as too frail because of co-morbid conditions or age, sup-
portive care without chance for remission may be the only
option, but investigating less toxic regimens or clinical
trials may offer acceptable alternatives [4]. The initial
symptoms of the two groups included fatigue, pallor, fever,
skin and mucous membrane bleeding, lower extremity
edema, and dizziness. There were no significant differ-
ences between the two groups with the exception of lower
extremity edema. In elderly patients, the co-morbidities of
hypertension, coronary heart disease, COPD, diabetes, and
liver disease may have similar presenting symptoms to
that of acute leukemia. A diagnosis of acute leukemia may
be missed in clinical practice based on the similarity of
presentations without extensive laboratory and other test-
ing. While a literature search revealed no specific studies
related to co-morbidities masking the onset of leukemia,
one case report described a patient with persistent cervical
lymphadenopathy with an initial diagnosis of toxoplasmo-
sis that masked non-Hodgkin’s lymphoma [19]. Disease
onset is often less evident in elderly patients who describe
multiple non-specific symptoms, and patients and families
may not pay attention to described symptoms leading to a
delay in diagnosis. A delay in seeking treatment may lead
to fewer options for the patient.
Complete blood count monitoring in elderly patients is
important in clinical practice for early diagnosis and
treatment of a variety of diseases, including leukemia.
Pancytopenia in peripheral blood was common in elderly
patients with newly diagnosed acute leukemia. Varying
degrees of anemia occurred in 93.44% of elderly patients
and 16.94% of elderly patients experienced severe anemia,
which were not significantly different than that of
younger patients. In elderly patients, the platelet count
was lower than normal, with 21.31% of patients with pla-
telets lower than 10 × 10
9 /L. The percentage of younger
patients whose platelet count was less than 10 × 10
9 /L
was 32.2%, which was significantly different from that of
elderly patients. The degree of bone marrow cellularity in
elderly patients was significantly reduced compared with
that of younger patients (33.3% vs. 49.2%) (Table 2).
This study found that AML accounted for 89.62% of
the leukemias in the elderly patient group, with M5
(acute monocytic leukemia) as the most common,
accounting for 48.63% of cases. ALL (acute lymphoblas-
tic leukemia) represented the remaining 10.38% in the
elderly patient group. In the younger group, the inci-
dence of ALL was higher (36.61%); with AML account-
ing for 63.4% of cases, of which M5 accounted for
23.50%. Our findings are similar to literature findings
that more than half of diagnosed AML patients are over
60 years of age [17].
The complete remission rate was 49.45% for all parti-
cipants in the elderly patient group after one to two
courses of regular chemotherapy which was significantly
Table 5 Causes of Chemotherapy Discontinuations in
Elderly and Younger Group Patients
Causes Young
(n = 69)*
Elderly
(n = 92)*
P value**
Severe clinical AL symptoms 15 (21.7) 39 (42.4) 0.06
Economic difficulty 46 (66.7) 34 (37.0) <0.001
Could not tolerate adverse effects 2 (2.9) 11 (12.0) 0.037
Unknown 6 (8.7) 8 (8.6) 0.896
*: The data were presented as number (%).
**: The c
2 test was used for the statistical analysis.
Table 4 Remission Status Stratified by FrenchAmerican-British Classification
ALL AML
Elderly
Group
(n = 19)
N (%)
Younger
Group
(n = 57)
N (%)
p-value
1 adjusted p
2 Elderly
Group
(n = 164)
N (%)
Younger
Group
(n = 116)
N (%)
p-value
1 adjusted p
2
Remission 0.274 0.422 0.022* 0.010*
status
Partial 5 (26.3) 17 (25.4) 41 (25.0) 21 (18.1)
Complete 5 (26.3) 30 (44.8) 40 (24.4) 46 (39.7)
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia.
1 Chi-square test was used.
2 Multiple logistic regression analysis that adjusted for smoking, alcohol use, lung infection, hypertension, diabetes, type of leukemia, platelet and bone marrow
cellularity.
* Indicates significant differences between two groups, p < 0.05.
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(Table 3). This was consistent with most reports in the
literature [9]. Reasons may include that elderly patients
have less immunity, may have drug resistance due to
physiologic changes associated with aging, often exhibit
more underlying diseases and cardio-pulmonary compli-
cations, their hematopoietic function recovers slowly,
and combination chemotherapy has significant side
effects. Some elderly patients only agreed to simple
examinations at the hospital, and refused bone marrow
biopsy, resulting in delayed treatment. When symptoms
progressed to high fever, bleeding, severe anemia, weight
loss, and failure to thrive, the optimal timing for treat-
ment was missed. Carefully explaining the reason for
diagnostic testing and examinations may mitigate some
treatment refusals when the elderly patient presents
with symptoms. Physiological age should be considered
as well as chronological age in treatment choices [11].
Future studies of newer agents with less severe side
effects and studies of clinicopharmacologic implications
of drug therapy in older patients are indicated.
The results of this study also showed that the percentage
of elderly patients with acute leukemia who discontinued
chemotherapy was 50.27%, which was significantly higher
than that of the younger group (37.3%). Family members
often worry that patients may not tolerate chemotherapy.
Traditional Chinese beliefs in families lead to the hope
that elderly patients can die at home, leading to a request
for discharge from the hospital rather than aggressive
treatment in some cases. In a study by Alam et al. [13], it
was reported that Canadian patients discontinued che-
motherapy prematurely in greater numbers than American
patients. Considering our results and that of other studies,
the question of whether cultural and national differences
influence therapy discontinuation should be investigated.
Financial difficulties were the second most common
reason (36.96%) that elderly patients discontinued che-
motherapy prematurely, while 66.7% of younger patients
discontinued chemotherapy for financial constraints.
Treatment of acute leukemia often leads to high medical
cost. Currently many families cannot afford high medi-
cal expenses as the National Health Care system and
the Social Welfare system have not been fully estab-
lished in China. In one study, patients from lower socio-
economic classes had poorer survival perhaps due to
class bias, greater co-morbidities, or ability to pay [20].
Psychological distress in cancer patients may impact
treatment decisions and additional studies are warranted
[21]. Patients and their families may choose to give up
treatment if costs cannot be managed. Identifying social
support measures may mitigate financial difficulties as a
reason for stopping chemotherapy.
Studies in the literature state that proactive identifica-
tion of patients at high risk of side effects is important
and aggressive management is crucial [2]. A discussion of
the multiple options for treatment of acute leukemia with
the patient and family is also important to select a regi-
men that delivers the best possible outcome with the
least toxic side effects [9]. Of the 50.27% of older newly
diagnosed AL patients who discontinued therapy in this
study, 11.96% of elderly patients discontinued che-
motherapy during the first or second course because they
could not tolerate the side effects of chemotherapy. In
addition to decreased normal physiological functions,
prognosis of acute leukemia in elderly patients is affected
by multiple poor prognostic factors. One third of older
patients experience combined vital organ diseases includ-
ing heart, brain, and kidney diseases, and a lower toler-
ance and slower clearance of cytotoxic drugs; so toxic
side effects may be increased accordingly [2]. Patients
exhibit different tolerances to chemotherapy based on
individual factors, and patients who are sensitive to che-
motherapy may still refuse treatment because of the ser-
iousness of side effects induced by chemotherapy.
Univariate analysis in this study also showed that adher-
ence to chemotherapy was poorer in older patients. The
percentage of elderly patients who discontinued che-
motherapy (50.27%) was significantly higher than in
younger patients (37.3%) (Table 3). In some cases, family
members could not deal with patients’ suffering, and
requested discharge from the hospital as soon as the dis-
ease condition was improved slightly. Patients either
remained at home after discharge or were admitted to
their local hospital. Older patients sometimes felt their
lives were less valuable. They requested discharge and dis-
continuation oftreatment because there was no improve-
ment in their illness even when they spent much of their
savings.
Limitations of the study include the retrospective nat-
ure of medical record reviews, limited demographic
information, lack of stratification by treatment regimen
in group comparisons, the fact that the two groups were
not matched other than by general diagnosis, and there
were no defined criteria to measure and compare toxicity.
E f f o r t ss h o u l db em a d et od e t ermine if cultural factors
play a more significant role than evident in our study.
Data was not captured that indicated whether the patient
or family made the decision to discontinue chemother-
apy. Future studies should incorporate a prospective
design, define additional data points for study, and con-
sider incorporating additional information requests about
non-clinical reasons for treatment decisions.
Conclusion
Acute monocytic leukemia is the most common acute
leukemia affecting elderly patients and cases of acute
leukemia in the older population are rising. In our study
we found that disease onset is less evident, and initial
Hu et al. BMC Cancer 2011, 11:224
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Page 7 of 8manifestations include fatigue and pallor, symptoms that
can indicate multiple disorders. In some elderly patients,
the disease is characterized by leukemia with low prolif-
erative activity, pancytopenia, and bone marrow hypo-
plasia, which may easily cause misdiagnosis or missed
diagnosis. A comprehensive history and physical, includ-
ing appropriate laboratory and other diagnostic tests are
indicated. Performance status and co-morbidities should
be considered in selecting an appropriate treatment regi-
men with attention to potential toxicity for the older
patient. Compliance to chemotherapy regimens is poor
in elderly patients and the percentage of patients discon-
tinuing chemotherapy is high. Thoughtful treatment
regimen selection to balance potential toxicity as well as
cost, prompt attention to side effects and toxicities dur-
ing treatment, and support for non-clinical issues such
as cultural beliefs, quality of life and cost of therapy are
important in the care of the elderly patient with acute
leukemia. Additional studies are needed to further
explore factors affecting elderly patients’ decisions to
initiate or stop acute leukemia treatment.
Additional material
Additional file 1: table S1: Schedules and chemotherapy agents for
treatment of AML and ALL patients. Additional file 1 contains a table
about Schedules and chemotherapy agents for treatment of AML and
ALL patients
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